RAPHAS
Korea - SeoulBiotechnology
Focus: RAPHAS is a Korean biotechnology company specializing in biodegradable microneedle drug delivery patches, currently commercializing XERAVA (eravacycline) for infectious diseases.
Profile data last refreshed 58m ago · AI intelligence enriched 1mo ago
Open Jobs
5+5 this month
Growing — net +5 jobs in 30d
5 jobs added vs 0 removed. Steady team buildout.
Should You Work at RAPHAS?
AI assessmentRAPHAS is a single-product revenue company with an innovative delivery platform but faces high concentration risk; consider only if seeking stability in a niche market with low advancement velocity.
Why Work Here
- Focused portfolio with one approved NDA product (XERAVA) at peak lifecycle, providing stable revenue through 2037 LOE
- Innovative drug delivery platform (biodegradable microneedles) offers differentiation in infectious disease treatment
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$0.788M Part DStable
Peak
Help build intelligence for RAPHAS
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.